Nieuws en video's - CRYOLIFE INC. - Pagina 2

CryoLife to Participate in Upcoming Virtual Investor Conferences PR Newswire ATLANTA, Aug. 6, 2020 ATLANTA , Aug. 6, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences. CryoLife's management team will present at the upcoming Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13 , 2020. The Company's virtual fireside chat...

CryoLife Reports Second Quarter 2020 Financial Results PR Newswire ATLANTA, July 30, 2020 ATLANTA , July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019 - Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency basis versus second quarter 2019 Completed $100.0 million convertible debt financing for general corporate purposes,...

CryoLife Announces Release Date and Teleconference Call Details for 2020 Second Quarter Financial Results PR Newswire ATLANTA, July 21, 2020 ATLANTA , July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET...

CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering PR Newswire ATLANTA, June 19, 2020 ATLANTA , June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under...

CryoLife Announces Offering of Convertible Senior Notes Due 2025 PR Newswire ATLANTA, June 18, 2020 ATLANTA , June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified...

CryoLife Initiates Enrollment in PROACT Xa Clinical Trial Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients PR Newswire ATLANTA, May 7, 2020 ATLANTA , May 7, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic valve can be...

CryoLife Reports First Quarter 2020 Financial Results PR Newswire ATLANTA, April 30, 2020 ATLANTA , April 30, 2020 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $66.4 million in the first quarter 2020 versus preliminary first quarter 2020 revenues of $65.5 million Total revenues decreased 2% and decreased 1% on a constant currency basis versus first quarter 2019 Excluding TMR, total revenues increased 1% and increased 2% on a constant currency basis...

CryoLife Announces Release Date and Teleconference Call Details for 2020 First Quarter Financial Results PR Newswire ATLANTA, April 16, 2020 ATLANTA , April 16, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 first quarter financial results will be released on Thursday, April 30, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m....

CryoLife Provides Business Update in Response to COVID-19 Pandemic PR Newswire ATLANTA, April 1, 2020 ATLANTA , April 1, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers. "We remain fully committed to supporting our employees while maintaining the demand and support for our products for customers and...

CryoLife Receives CE Mark for E-vita Open NEO™ Hybrid Stent Graft Newest Hybrid Stent Graft Offering Enhances Ease-of-Use PR Newswire ATLANTA, March 4, 2020 ATLANTA , March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO , a hybrid stent graft system for the treatment of aortic arch disease. Aortic arch disease includes both aortic aneurysms and...

CryoLife Receives CE Mark for On-X® Ascending Aortic Prosthesis PR Newswire ATLANTA, Feb. 27, 2020 ATLANTA , Feb. 27, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning native or prosthetic heart valves...

CryoLife Reports Fourth Quarter and Full Year 2019 Financial Results PR Newswire ATLANTA, Feb. 13, 2020 ATLANTA , Feb. 13, 2020 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $69.7 million in the fourth quarter of 2019, reflecting year over year growth of 3% and a 4% increase on a non-GAAP constant currency basis, both compared to the fourth quarter of 2018 On-X ® revenues increased 18%, and 18% on a non-GAAP constant currency basis, both compared to the...

CryoLife Announces Release Date and Teleconference Call Details for 2019 Fourth Quarter and Year-end Financial Results PR Newswire ATLANTA, Jan. 30, 2020 ATLANTA , Jan. 30, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday, February 13, 2020 after the market closes. On that day, the Company will hold a teleconference call...

CryoLife Receives FDA Authorization to Commence PROACT Xa Clinical Trial Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients PR Newswire ATLANTA, Dec. 23, 2019 ATLANTA , Dec. 23, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an Investigational New Drug (IND) application to begin the...

CryoLife Receives CE Mark for E-nya Thoracic Stent Graft Product Launch Anticipated in the First Quarter 2020 PR Newswire ATLANTA, Dec. 2, 2019 ATLANTA , Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections....

CryoLife Receives CE Mark for E-nside Thoraco-abdominal Stent Graft First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology PR Newswire ATLANTA, Dec. 2, 2019 ATLANTA , Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside TAAA multibranch stent graft system for the endovascular treatment of thoraco-abdominal aneurysms....

CryoLife Reports Third Quarter 2019 Financial Results PR Newswire ATLANTA, Oct. 30, 2019 ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ® revenues increased 12%, and 12% on a non-GAAP constant currency basis, both compared to the third quarter of 2018...

CryoLife Announces Release Date and Teleconference Call Details for 2019 Third Quarter Financial Results PR Newswire ATLANTA, Oct. 16, 2019 ATLANTA , Oct. 16, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 third quarter financial results will be released on Wednesday, October 30, 2019 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 5:30 p.m....

CryoLife Enters Into Distribution Agreement with Endospan Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET PR Newswire ATLANTA, Sept. 11, 2019 ATLANTA , Sept. 11, 2019 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into distribution and credit facility...

CryoLife to Participate in Upcoming Investor Conferences PR Newswire ATLANTA, Aug. 29, 2019 ATLANTA , Aug. 29, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences. CryoLife's management will be presenting at the Morgan Stanley 17th Annual Healthcare Conference in New York, New York on Wednesday, September 11, 2019 at 11:40 a.m. ET and will feature...